ENERGY BEVERAGES: MAIN COMPONENTS, EFFICACY, AND SAFETY

Download full text PDF
Issue: 
10
Year: 
2016

Professor R. Khanferyan, MD Federal Research Center for Nutrition, Food Biotechnology and Safety, Moscow

The paper gives an update on the consumption of energy beverages, on the pharmacokinetics and pharmacodynamics of main drink ingredients, such as caffeine and taurine, as well as on an investigation of the safety of biological active components in energy drinks.

Keywords: 
energy beverages
caffeine
taurine
dietary supplements
safety



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Scientific Opinion on the safety of caffeineEFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) // EFSA J. – 2015; 13 (5): 4102.
  2. Dorfman L., Jarvik M. Comparative stimulant and diuretic actions of caffeine and theobromine in man // Clin. Pharmacol. Ther. – 1970; 11 (6): 869–72.
  3. Boothby W., Rowntree L. Drugs and basal metabolism // J. Pharmacol. Exp. Ther. – 1924; 22: 99–108.
  4. Haldi J., Bachmann G., Ensor C. et al. The effects of various amounts of caffeine on the gaseous exchange and the respiratory quotient in man // J. Nutr. – 1941; 21: 307.
  5. Miller D., Stock M., Stuart J. The effects of caffeine and carnitine on the oxygen consumption of fed and fasted subjects // Proc. Nutr. Soc. – 1974; 33: 28
  6. A.Acheson K., Zahorska-Markiewicz B. Pittet Ph. et al. Caffeine and coffee their influence on metabolic rate and substrate utilization in normal weight and obese individuals // Am. J. Clin. Nutr. – 1980; 33 (5): 989–97.
  7. Nathanson J. Caffeine and related methylxanthines: possible naturally occurring pesticides // Science. – 1984; 226 (4671): 184–7.
  8. Mathavan S., Premalatha Y., Christopher M. Effects of caffeine and theophylline on the fecundity of four lepidopteran species // Exp Biol. – 1985; 44 (2): 133–8.
  9. Hollingsworth R., Armstrong J., Campbell E. Caffeine as a repellent for slugs and snails // Nature. – 2002; 417: 915–6.
  10. Barone J., Roberts H. Caffeine consumption // Food Chem. Toxicol. – 1996; 34: 119–29.
  11. Juliano L., Griffiths R. A critical review of caffeine withdrawal: Empirical validation of symptoms and signs, incidence, severity, and associated features // Psychopharmacology. – 2004; 176: 1–29.
  12. Drewnowski A., Rehm C. Sources of caffeine in diets of US children and adults: trends by beverage type and purcgase location // Nutrients. – 2016; 8: 154–66.
  13. Kalinin A.Ja. Kofein – drug ili vrag? // Kompetentnost'. – 2014; 9–10 13. (120–121): 43–51.
  14. Bessonov V.V., Hanfer'jan R.A. Kofein v pitanii. Soobschenie I. Postuplenie s pitaniem i regulirovanie // Vopr. pitanija. – 2015; 4: 119–27.
  15. Fredholm B., B15. ättig K., Holmén J. et al. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use // Pharmacol. Rev. – 1999; 51 (1): 83–133.
  16. Magkos F., Kavouras S. Caffeine use in sports, pharmacokinetics in man, and cellular mechanisms of action // Crit. Rev. Food Sci. Nutr. – 2005; 45: 535–62.S.
  17. Teekachunhatean N., Tosri N., Rojanasthien S. et al. Pharmacokinetics of Caffeine following a Single Administration of Coffee Enema versus Oral Coffee Consumption in Healthy Male Subjects // ISRN Pharmacology. – 2013; Article ID 147238. http://dx.doi.org/10.1155/2013/147238
  18. Perera V., Gross A., McLachlan A. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma // Biomed. Chromatogr. – 2010; 24 (10): 1136–44.
  19. Kamimori G., Karyekar C., Otterstetter R. et al. The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers // Inter. J. Pharm. – 2002; 234 (1–2): 159–76
  20. Fredholm B., B20. ättig K., Holmén J. et al. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use // Pharmacol. Rev. – 1999; 51 (1): 83–133.
  21. Arnaud M. The pharmacology of caffeine // Prog. Drug Res. – 1987; 31: 21. 273–313.
  22. Schneider H., Ma L., Glatt H. Extractionless method for the determination of urinary caffeine metabolites using high-performance liquid chromatography coupled with tandem mass spectrometry // J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. – 2003; 789 (2): 227–37.
  23. Kot M., Daniel W. Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat // Pharmacol. Rep. – 2008; 60 (6): 789–97.
  24. Gonzalez A., Hoffman J., Wells A. et al. Effects of Time-Release Caffeine Containing Supplement on Metabolic Rate, Glycerol Concentration and Performance // J. Sports Sci. Med. – 2015; 14 (2): 322–32.
  25. Astrup A., Breum L., Toubro S. et al. The effect and safety of an ephedrine/ caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial // Int. J. Obes. Relat. Metab. Disord. – 1992; 16 (4): 269–77.
  26. Huxtable R. Physiological actions of taurine // Physiolog. Rev. – 1992; 72 26. (1): 101–63.
  27. SchafferS. W., ItoT, Azuma J. Clinical significance of taurine // Amino 27. Acids. – 2014; 46 (1): 1–5.
  28. De Luca A., Pierno S., Conte Camerino D. Taurine: the appeal of a safe 28. amino acid for skeletal muscle disorders // J. Transl. Med. – 2015; 13: 243.
  29. Faggiano A., Melis D., Alfieri R. et al. Sulfur amino acids in Cushing’s 29. disease: insight in homocysteine and taurine levels in patients with active and cured disease // J. Clin. Endocrinol. Metab. – 2005; 90: 6616–22.
  30. Sturman J. Taurine in development // J. Nutr. – 1988; 118: 1169–76.30.
  31. Jansson T. Amino acid transporters in the human placenta // Pediatr. 31. Res. – 2001; 49: 141–7.
  32. Tappaz M. Taurine biosynthetic enzymes and taurine transporter: 32. molecular identification and regulations // Neurochemical. Research. – 2004; 29 (1): 83–96.
  33. Ramamoorthy S., Leibach F., Mahesh V. et al. Functional characterization 33. and chromosomal localization of a cloned taurine transporter from human placenta // Biochem. J. – 1994; 300: 893–900.
  34. Norberg S., Powell T., Jansson T. Intrauterine growth restriction is 34. associated with a reduced activity of placental taurine transporters // Pediatr. Res. – 1998; 44: 233–8.
  35. Na-Young Lee, Young-Sook Kang.mailto:yskang@sookmyung.ac.kr Regulation of taurine transport at the blood-placental barrier by calcium ion, PKC activator and oxidative stress conditions // J. Biomed. Sci. – 2010; 17 (Suppl. 1): 37
  36. Imae M., Asano T., Murakami S. Potential role of taurine in the prevention of diabetes and metabolic syndrome // Amino Acids. – 2014; 46 (1): 81–8.
  37. Ripps H., Shen W. Review: taurine: a “very essential” amino acid // Molecular Vision. – 2012; 18: 2673–86.
  38. Ito T., Schaffer S., Azuma J. The potential usefulness of taurine on diabetes mellitus and its complications // Amino Acids. – 2012; 42 (5): 1529–39.
  39. Hayes K., Carey R., Schmidt S. Retinal degeneration associated with taurine deficiency in the cat // Science. – 1975; 188 (4191): 949–51.
  40. Zeng K., Xu H., Mi M. et al. Effects of taurine on glial cells apoptosis and taurine transporter expression in retina under diabetic conditions // Neurochemical Research. – 2010; 35 (10): 1566–74.
  41. Hansen S. The role of taurine in diabetes and the development of diabetic complications // Diabet. Metab. Res. Rev. – 2001; 17 (5): 330–46.
  42. Di Leo M., Santini S., Cercone S. et al. Chronic taurine supplementation ameliorates oxidative stress and Na+ K+ ATPase impairment in the retina of diabetic rats // Amino Acids. – 2002; 23 (4): 401–6.
  43. Di Leo M., Ghirlanda G., Gentiloni Silveri N. et al. Potential therapeutic effect . of antioxidants in experimental diabetic retina: a comparison between chronic taurine and vitamin E plus selenium supplementations // Free Radical Research. – 2003; 37 (3): 323–30.
  44. Han X., Patters A., Jones D. et al. The taurine transporter: mechanisms of regulation // Acta Physiologica. – 2006; 187 (1–2): 61–73.
  45. Franconi F., Miceli M., Fazzini A. et al. Taurine and diabetes. Humans and experimental models. In Advances in Experimental Medicine and Biology / New York, NY, USA: Springer, 1996; 579–82.
  46. Franconi F., Loizzo A., Ghirlanda G. et al. Taurine supplementation and diabetes mellitus // Curr. Opin. Clin. Nutr. Metab. Care. – 2006; 9 (1): 32–6.
  47. Baynes J., Thorpe S. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm // Diabetes. – 1999; 48 (1): 1–9.
  48. Napol Z., Seghieri G., Bianchi L. et. al. Taurine Transporter Gene Expression in Mononuclear Blood Cells of Type 1 Diabetes Patients // J. Diabetes Res. – 2016: 7313162. Published online 2016 Feb 3.
  49. Proskurjakova T.V., Shohonova V.A., Anohin P.K. i dr. Bezalkogol'nye 49. kofeinsoderzhaschie tonizirujuschie napitki: eksperimental'noe issledova-nie // Narkologija. – 2015; 2: 18–30.